Newsletter April 2019

Open the PDF file below to read the full newsletter.

In this issue:

  • KL1333 in clinical trial – The starting pistol has been fired
  • Interview with MELAS patient Roger Kjell 
  • BioStock’s article NeuroVive wants to help patients with mitochondrial diseases

Read more about us and subscribe:

Follow us on LinkedIn

View our videos, interviews and presentations by subscribing to our YouTube channel


About Us

Abliva AB is a leader in mitochondrial medicine, with one project in clinical phase I (KL1333) for chronic treatment of primary mitochondrial diseases and one project, in preparation for clinical trials (NV354), for treatment of primary mitochondrial diseases with Complex I deficiency. NeuroSTAT for traumatic brain injury (TBI) is ready to enter a clinical phase II efficacy study. The R&D portfolio also consists of early projects. Abliva’s ambition is to take drugs for primary mitochondrial diseases through clinical development and all the way to market, with or without partners. For the TBI and NASH projects the goal is to enter strategic partnerships. A subset of compounds under the NVP015 program has been licenced to Fortify Therapeutics, a BridgeBio company, for local treatment development of Leber’s Hereditary Optic Neuropathy (LHON). Abliva is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).




Documents & Links